FiMM - Institute for Molecular Medicine Finland

FIMM is a translational research institute focusing on human genomics and personalized medicine at the Helsinki Institute for Life Science of the University of Helsinki. FIMM has a driving mission to perform innovative research on patients and populations targeted towards understanding drivers of health and disease and delivering improvements to the safety, efficacy, and efficiency of healthcare in Finland and beyond. Our research is primarily organised around three Grand Challenge programs: (1) the development of individualised cancer medicine; (2) novel diagnostics via imaging of tissue and cells; and (3) the use of genomics and epidemiology to better understand and predict disease. The FIMM Technology Centre and Biobanking Infrastructures, networked with several European ESFRIs, are critical partners to all of these research efforts. FIMM has over 250 employees representing almost 30 nationalities, more than 20 group leaders, and a budget of 25 M€ with 80% of the funding coming from external grants. FIMM is also a Finnish node of the Nordic EMBL Partnership for Molecular Medicine.

FIMM

P.O.Box 20

University of Helsinki, Finland
Mark Daly
Mark Daly
Director

‘The EU-LIFE community effort helps us anticipate, understand and respond efficiently and effectively to European policy and research initiatives - a great benefit to researchers in times of change.’

Professor Mark Daly, Director of FIMM

Facts and Figures

85%

of the funding

from competitive sources

240

Scientific Articles

per year

500K

Finns

will participate in the ambitious FinnGen study coordinated by FIMM